TransBioLine Archives - Tamirna - stability for life

TAmiRNA at EUROTOX 2024 in Copenhagen

On September 10, our CEO & CSO, Dr. Matthias Hackl, will discuss “Small RNA-sequencing based discovery of microRNAs for CNS-injury biomarkers” during the EUROTOX Short Orals Session. He’ll highlight the efforts of TAmiRNA and the IMI consortium TransBioLine in advancing microRNAs as biomarkers of drug-induced brain injury. TAmiRNA will also bring a poster (P06-01) to the conference, authored by Senior Scientist, Dr. Kseniya Khamina-Kotisch, on “NGS-based discovery of microRNA biomarkers of drug-induced pancreatic injury (DIPI),” showcasing the merits of small RNA-sequencing (miND) for biomarker discovery. Don’t miss this opportunity to explore TAmiRNA's latest advancements in microRNA diagnostics. Reach out to Matthias directly to meet and discuss our latest developments and how TAmiRNA's services can assist your business! TAmiRNA [...]

TAmiRNA is part of the international IMI2 project “Translational Safety Biomarker Pipeline”

2023-03-10T11:01:16+01:00April 30th, 2019|biomarkers, drug development, drug discovery, exosomes, liquid biopsies, microRNAs, Personalized medicine, safety|Comments Off on TAmiRNA is part of the international IMI2 project “Translational Safety Biomarker Pipeline”

Early and reliable detection and monitoring of adverse events is essential for improving of patient safety, reducing late attrition of drug candidates, and enhancing understanding of toxic mechanisms. The Translational Safety Biomarker Pipeline (TransBioLine) project will focus on development of biomarkers of injury for liver, kidney, pancreas, vasculature, central nervous system (CNS) and the development of non-invasive microRNA biomarkers using liquid biopsies. The project is coordinated by the University of Zurich with Pfizer as industry lead, and involves 27 partners (pharmaceutical companies, small and medium-sized enterprises, and academic institutions) from ten European countries and the United States of America. With a total budget of € 28 million, the EU and the pharmaceutical companies involved are financing the [...]